Skip to main content

Table 1 Patient characteristics and GIP serum levels

From: The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury

Parameter

Control

(no myocardial infarction)

(n=631)

STEMI

(n=100)

GIP—pg/mL

271.54 (70.12–542.41)

216.82 (52.37–443.07)

Age—years

65.86 ± 12.53

62.24 ± 11.21

BMI—kg/m²

28.51 ± 5.75

26.17 ± 3.79

Male—No. (%)

475 (75.28)

84 (84)

Type 2 Diabetes—No. (%)

211 (33.44)

24 (24)

Hypertension—No. (%)

470 (74.84)

55 (55)

Smoker—No. (%)

123 (19.59)

47 (47)

Creatinine—mg/dL

1 (0.9–1.2)

0.9 (0.8–1.1)

eGFR—mL/min/1,73 m²

71.54 ± 22.89

81.76 ± 18.25

CK—U/L

87 (61–142)

197 (110–481)

Troponin—pg/mL

18 (10–38)

1428.5 (352.5–-2811)

CRP—mg/L

2.2 (2.2–9)

13 (7–33)

Leukocytes—nL

7.57 ± 2.32

9.22 ± 2.55

Coronary artery disease—No. (%)

457 (72.42)

100 (100)

  1. Continuous variables are expressed as mean ± SD or median (Q1–Q3) in case of heavily skewed data. Categorical variables are shown as absolute (No.) and relative frequencies (%)
  2. BMI body-mass-index, CK creatine kinase, CRP C-reactive protein, eGFR estimated glomerular filtration rate, GIP glucose-dependent insulinotropic polypeptide, STEMI ST-elevation myocardial infarction